PCM
MYGN icon

Pinz Capital Management’s Myriad Genetics MYGN Stock Holding History

Pinz Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-81,802
Closed -$2.06M – 245
2022
Q1 		$2.06M Buy
+81,802
New +$2.09M 1.29% 26

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pinz Capital Management's MYGN Position: Q2 2022 in Review

Pinz Capital Management sold out of Myriad Genetics (MYGN) in Q2 2022, closing a stake of 81,802 shares — an estimated $2.06M sold.

Pinz Capital Management first reported a position in MYGN in Q1 2022 and held it in 1 quarter. The position peaked at $2.06M in Q1 2022. 198 funds tracked by Wall St. Rank hold MYGN as of Q2 2022.

  • Pinz Capital Management reported no remaining Myriad Genetics position as of Q2 2022 after selling out during the quarter.
  • Pinz Capital Management sold 81,802 Myriad Genetics shares in Q2 2022, an estimated $2.06M.
  • Pinz Capital Management first reported a position in Myriad Genetics in Q1 2022 and held it in 1 quarter.
  • Pinz Capital Management's Myriad Genetics position peaked at $2.06M in Q1 2022.
  • 198 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2022.

Based on Pinz Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.